Document is current
Any future updates will be listed below
-
Authors
Beauverd, Yan https://orcid.org/0000-0002-7971-4326
Ianotto, Jean-Christophe https://orcid.org/0000-0001-9074-7287
Thaw, Kyaw Htin
Sobas, Marta
Sadjadian, Parvis https://orcid.org/0000-0002-6380-6840
Curto-Garcia, Natalia
Shih, Lee-Yung https://orcid.org/0000-0003-1866-7922
Devos, Timothy
Krochmalczyk, Dorota
Galli, Serena
Bieniaszewska, Maria https://orcid.org/0000-0002-5704-0244
Seferynska, Ilona
McMullin, Mary Frances https://orcid.org/0000-0002-0773-0204
Armatys, Anna
Spalek, Adrianna
Waclaw, Joanna
Zdrenghea, Mihnea Tudor
Legros, Laurence
Girodon, Francois https://orcid.org/0000-0003-3151-1068
Lewandowski, Krzysztof https://orcid.org/0000-0003-0992-2020
Bellosillo, Beatriz
Samuelsson, Jan
Abuin Blanco, Aitor
Cony-Makhoul, Pascale
Collins, Angela
James, Chloe
Kusec, Rajko
Lauermannova, Marie
Noya, Maria Soledad https://orcid.org/0009-0008-4875-3438
Skowronek, Malgorzata
Szukalski, Lukasz
Szmigielska-Kaplon, Anna
Wondergem, Marielle
Dudchenko, Iryna https://orcid.org/0000-0002-7038-4455
Gora-Tybor, Joanna
Laribi, Kamel
Kulikowska de Nałęcz, Anna
Demory, Jean-Loup
Le Dû, Katell
Zweegman, Sonja
Besses Raebel, Carlos
Skoda, Radek C. https://orcid.org/0000-0002-3626-9496
Giraudier, Stephane https://orcid.org/0000-0002-1817-2236
Griesshammer, Martin
Kiladjian, Jean-Jacques
Harrison, Claire N
- License Information
-
More Information
Article History
Received: 13 August 2024
Revised: 11 December 2024
Accepted: 18 February 2025
First Online: 12 March 2025
Competing interests
: YB reports advisory board membership (AOP), speaker fee (AOP), congress support (Abbvie), J-CI reports advisory board membership (Abbvie, Novartis), grant (Novartis), congresses support (Novartis, Pfizer, GSK), MS reports lectures (AOP Orphan, BMS, GSK, Novartis), conferences (Novartis), membership advisory board (BMS, GSK), TD reports consultancy fee (GSK, Morphosys, BMS, Novartis, Incyte) and honorarium (Janssen, Sobi, Alexion), MFM reports advisory board membership (Novartis, BMS, Incyte, GSK), speaker bureau participation (Novartis, AOP, GSK), and clinical trial support (BMS, AOP, GSK), LL reports research funding (Amgen, BMS, Incyte, Novartis), honoraria (BMS, GSK, Novartis, Pfizer), hospitality (Novartis, Pfizer), FG reports sponsored UPR (Abbvie), CJ reports conference (Abbvie), MW reports speaker fees (AOP), educational talks (Novartis, BMS, Sanofi), data safety monitoring board (Keros therapeutics), MG report consultancy (AOP Orphan, Novartis, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, Sierra, Lilly, GSK) and honorarium (AOP Orphan, Novartis, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, Sierra, Lilly, GSK), J-JK reports consultancy fee (Novartis, GSK, Abbvie), advisory boards membership (BMS, Incyte, AOP, PharmaEssentia), CNH reports research funding (Celgene (BMS), Constellation, GSK, Novartis), and Advisory board membership (AbbVie, AOP, BMS, CTI, IMAGO, Incyte, Novartis, Galacteo, Geron, GSK, Incyte, Janssen, Keros, MSD, SOBI, Morphosys). The remaining authors declare no competing financial interests.
